{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:18:29Z","timestamp":1772853509192,"version":"3.50.1"},"reference-count":11,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cytotoxic T lymphocyte\u2013associated antigen-4 (CTLA-4) insufficiency is a rare disease belonging to inborn errors of immunity. Most cases of patients with CTLA-4 insufficiency are diagnosed in adults, therefore it is not a common problem in the clinical practice of pediatricians. However, it is worth noticing that most cases described in the literature show the first symptoms of the disease before the age of 18, but the phenotypic variability of patients complicates and delays the diagnostic process.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case description<\/jats:title><jats:p>Herein, we report a case of an almost 4-year-old patient whose first symptom of CTLA-4 insufficiency was thrombocytopenia after an upper respiratory tract infection, suggesting the diagnosis of primary immune thrombocytopenia, often occurring in pediatric patients. Due to the addition of symptoms suggesting a proliferative disease in this patient (pancytopenia, enlargement of lymph nodes, liver and spleen), a bone marrow biopsy was performed 11 months later, which did not confirm a hematopoietic tumor. Two years after the first symptoms appeared, the patient was referred for next-generation sequencing genetic testing, which confirmed the presence of a pathological CTLA-4 variant (c.356T&amp;gt;C). Due to the patient\u2019s lack of response to the pharmacological treatment and the intensification of autoimmune symptoms that threatened the patient\u2019s life, the patient underwent hematopoietic stem cell transplantation (HSCT) 34 months after the first occurrence of symptoms. After HSCT, the patient is alive and does not present any symptoms of autoimmunity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The first symptoms of some diseases classified as inborn errors of immunity are non-specific and may delay the final diagnosis. Therefore, it seems extremely important that practicing pediatricians should take into account inborn errors of immunity in the differential diagnosis of autoimmune diseases.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1484467","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T06:10:23Z","timestamp":1731910223000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Case report: Pediatric patient with severe clinical course of CTLA-4 insufficiency treated with HSCT"],"prefix":"10.3389","volume":"15","author":[{"given":"Katarzyna","family":"Drabko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Zarychta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Kowalczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Cienkusz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01289-3","article-title":"Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee","volume":"42","author":"Tangye","year":"2022","journal-title":"J Clin Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s12016-021-08881-2","article-title":"Novel genetic discoveries in primary immunodeficiency disorders","volume":"63","author":"Redmond","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: From mechanism to autoimmune therapy","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3746","article-title":"Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations","volume":"20","author":"Schubert","year":"2014","journal-title":"Nat\u00a0Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/all.15331","article-title":"Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency","volume":"77","author":"Catak","year":"2022","journal-title":"Allergy"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.04.039","article-title":"Therapeutic options for CTLA-4 insufficiency","volume":"149","author":"Egg","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.055","article-title":"Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects","volume":"142","author":"Schwab","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1833029","article-title":"Evaluation of expression of LRBA and CTLA-4 proteins in common variable immunodeficiency patients","volume":"51","author":"Salami","year":"2022","journal-title":"Immunol Invest"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s40348-023-00167-1","article-title":"Autoimmune lymphoproliferative immunodeficiencies (ALPID) in childhood: breakdown of immune homeostasis and immune dysregulation","volume":"10","author":"Toskov","year":"2023","journal-title":"Mol Cell Pediatr"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108779","article-title":"Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency","volume":"229","author":"Lanz","year":"2021","journal-title":"Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"S0091","DOI":"10.1016\/j.jaci.2024.08.020","article-title":"Hematopoietic stem cell transplantation for CTLA-4 insufficiency across Europe: A European Society for Blood and Marrow Transplantation Inborn Errors Working Party study","volume":"30","author":"Tsilifis","year":"2024","journal-title":"J Allergy Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1484467\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T06:10:24Z","timestamp":1731910224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1484467\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":11,"alternative-id":["10.3389\/fimmu.2024.1484467"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1484467","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"article-number":"1484467"}}